Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 2016, Article ID 9864047, 8 pages
Review Article

New Progress of Epigenetic Biomarkers in Urological Cancer

Peng Wu,1,2,3,4 Ziyi Cao,1,2,4,5 and Song Wu1,2,4,6

1Department of Urological Surgery, The Affiliated Luohu Hospital of Shenzhen University, Shenzhen University, Shenzhen 518000, China
2Shenzhen Following Precision Medical Institute, Shenzhen Luohu Hospital Group, Shenzhen 518000, China
3First Clinical Medical College, Anhui Medical University, Hefei 230032, China
4Shenzhen Second People’s Hospital, 1st Affiliated Hospital of Shenzhen University, Shenzhen 518037, China
5Medical College, Shenzhen University, Shenzhen 518060, China
6Shenzhen Gene Detection Public Service Platform of Clinical Application, Shenzhen Luohu Hospital Group, Shenzhen 518000, China

Received 19 May 2016; Accepted 30 June 2016

Academic Editor: Maria L. Poeta

Copyright © 2016 Peng Wu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Urological cancers consist of bladder, kidney, prostate, and testis cancers and they are generally silenced at their early stage, which leads to the loss of the best opportunity for early diagnosis and treatment. Desired biomarkers are scarce for urological cancers and current biomarkers are lack of specificity and sensitivity. Epigenetic alterations are characteristic of nearly all kinds of human malignances including DNA methylation, histone modification, and miRNA regulation. Besides, the detection of these epigenetic conditions is easily accessible especially for urine, best target for monitoring the diseases of urinary system. Here, we summarize some new progress about epigenetic biomarkers in urological cancers, hoping to provide new thoughts for the diagnosis, treatment, and prognosis of urological cancers.